Trending Topic

4 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

The International Society of Dermatology (ISD) stands at the forefront of advancing global skin health through education, collaboration and outreach.1 Established with a mission to bridge disparities in dermatological care worldwide, the ISD has become a vital hub for connecting the dermatology community, encouraging scientific exchange and promoting equitable access to dermatologic knowledge and services. […]

Victoria P. Werth: The phase 3 DeterMine trial of lenabasum in dermatomyositis Recent content from our partner site touchIMMUNOLOGY

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Oct 11th 2023

DeterMine (NCT03813160) was a phase 3 randomized, double-blind, placebo-controlled study investigating the efficacy and safety of lenabasum for the treatment of dermatomyositis. It was a pleasure to talk with Prof. Victoria P. Werth (University of Pennsylvania, Philadelphia, PA, USA) to discuss the aims, design, eligibility criteria and findings of the phase 3 study.

This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.

The abstract ‘Cutaneous Manifestations, Clinical Trials, Safety Efficacy and Safety of Lenabasum in the Phase 3 DeterMine Trial in Dermatomyositis.‘ (Abstract number: 0173) was presented at the ACR Convergence, November 10–14, 2022.

Questions

  1. Could you tell us a little about dermatomyositis and the unmet needs in its treatment? (0:16)
  2. What is lenabasum and what is the rationale for its use in this indication? (2:38)
  3. What were the aims, design and eligibility criteria of your phase 3 study? (3:29)
  4. What were the primary and secondary outcome measures and how well were they achieved? (5:49)
  5. Why do you think these endpoints were not met, and what were the positive outcomes of this study? (7:26)

Disclosures: Victoria P. Werth discloses receiving grants from: Celgene, Amgen, Janssen, Biogen, Gilead, Viela, Horizon therapeutics, and Ventus; consulting for: Astra-Zeneca, Pfizer, Biogen, Celgene, Resolve, Janssen, Gilead, Lilly, BMS, Nektar, Abbvie, Viela, GSK, EMD Serona, Sanofi, Anaptysbio, Amgen, Merck Kyowa Kirin, Rome Therapeutics, and Xencor; serving on advisory boards for: Lupus Foundation of America; and receiving honorarium from: Astra-Zeneca, Pfizer, Biogen, Celgene, Resolve, Janssen, Gilead, Lilly, BMS, Nektar, Abbvie, Viela, GSK, EMD Serona, Sanofi, Anaptysbio, Amgen, Merck Kyowa Kirin, Rome Therapeutics, and Xencor.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.

Filmed in coverage of the ACR Convergence 2022.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup